Arrowhead Pharmaceuticals Quarterly Cash Flow Statement
NASDAQ: ARWRHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Arrowhead Pharmaceuticals free cash flow
In the quarter ended Jun 30, 2026, Arrowhead Pharmaceuticals generated -$177.5 million of operating cash flow and spent $3.9 million on capital expenditures. That left free cash flow of -$181.3 million, a free-cash-flow margin of -241.0% of revenue.
Summary generated from market data by MetaCap's automated system. Methodology
Arrowhead Pharmaceuticals cash flow statement (quarterly)
| Quarter (USD) | Q3 20262026-06-30 | Q2 20262026-03-31 | Q1 20262025-12-31 | Q4 20252025-09-30 | Q3 20252025-06-30 | Q2 20252025-03-31 | Q1 20252024-12-31 | Q4 20242024-09-30 | Q3 20242024-06-30 | Q2 20242024-03-31 | Q1 20242023-12-31 | Q4 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -178.92M | -137.57M | 28.24M | 16.12M | -178.65M | 367.86M | -175.22M | -173.34M | -173.98M | -127.00M | -135.38M | -111.02M |
| Net Income growth (YoY) | — | -137.40% | — | — | — | — | — | — | — | -366.37% | — | — |
| Depreciation & Amortization | 6.20M | 5.90M | 6.00M | 6.00M | 5.80M | 5.60M | 4.80M | 4.60M | 4.40M | 4.10M | 3.80M | 3.30M |
| Stock-Based Compensation | 14.87M | 16.67M | 19.37M | 19.09M | 13.04M | 16.03M | 15.21M | 19.47M | 17.05M | 17.75M | 19.69M | 18.18M |
| Change in Working Capital | -41.56M | 188.53M | -60.56M | -37.14M | -16.76M | 44.88M | -7.71M | 10.79M | 25.18M | 2.75M | -14.67M | 14.01M |
| Operating Cash Flow | -177.47M | 84.44M | 13.48M | 20.49M | -154.72M | 460.05M | -146.27M | -137.22M | -115.42M | -92.38M | -117.84M | -25.93M |
| Capital Expenditures | -3.85M | -2.56M | -2.15M | -7.49M | -2.36M | -5.30M | -7.52M | -24.29M | -14.45M | -34.08M | -68.66M | -63.91M |
| Investing Cash Flow | 43.68M | -894.28M | -23.74M | 72.62M | 141.39M | -420.21M | 76.91M | -222.92M | 6.95M | -268.94M | 64.84M | 30.51M |
| Financing Cash Flow | -449.00K | 795.72M | -14.75M | 3.67M | -42.68M | 92.38M | 20.63M | 389.09M | 50.39M | 430.78M | 267.00K | 821.00K |
| Net Change in Cash | -134.24M | -14.12M | -25.01M | 96.78M | -56.01M | 132.22M | -48.73M | 28.95M | -58.08M | 69.46M | -52.73M | 5.40M |
| Free Cash Flow | -181.32M | 81.88M | 11.33M | 13.00M | -157.08M | 454.76M | -153.79M | -161.50M | -129.87M | -126.45M | -186.50M | -89.83M |
This table shows 12 quarterly periods of Arrowhead Pharmaceuticals's cash flow statement, from Q3 2026 back to Q4 2023, across 10 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow ARWR's reporting calendar. What is a cash flow statement?